Literature DB >> 10022445

Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16.

M Kjellman1, L Roshani, B T Teh, O P Kallioniemi, A Höög, S Gray, L O Farnebo, M Holst, M Bäckdahl, C Larsson.   

Abstract

To identify chromosomal regions that may contain loci for tumor suppressor genes involved in adrenocortical tumor development, a panel of 60 tumors (39 carcinomas and 21 adenomas) were screened for loss of heterozygosity. Although the vast majority of loss of heterozygosity (LOH) were detected in the carcinomas and involved chromosomes 2, 4, 11, and 18, only few were found in the adenomas. Therefore, 2 loci that harbor the familial cancer syndromes Carney complex in 2p16 and the multiple endocrine neoplasia type 1 gene in 11q13 were further studied in 27 (13 carcinomas and 14 adenomas) of the 60 tumors. Detailed analysis of the 2p16 region mapped a minimal area of overlapping deletions to a 1-centimorgan region, which is separate from the Carney complex locus. LOH for a microsatellite marker (PYGM), very close to the MEN1 gene, was detected in all 8 informative carcinomas (100%) and in 2 of 14 adenomas. Of the 27 cases analyzed in detail, 13 cases (11 carcinomas and 2 adenomas) showed LOH on chromosome 11 and was therefore selected for MEN1 gene mutation analysis. In 6 cases a common polymorphism (Asp418Asp) was found, but no mutation was detected. In conclusion, our data indicate the existence of tumor suppressor genes at multiple chromosomal locations, whose inactivations are involved in the development of adrenocortical carcinomas. Loss of genetic material from 2p16 was strongly associated with the malignant phenotype, as it was seen in almost all carcinomas but not in any of the adenomas. LOH in 11q13 also occurred frequently in the carcinomas, but was not associated with a MEN1 mutation, suggesting the involvement of a different tumor suppressor gene on this chromosome.

Entities:  

Mesh:

Year:  1999        PMID: 10022445     DOI: 10.1210/jcem.84.2.5506

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  22 in total

1.  Antineoplastic effects of decitabine, an inhibitor of DNA promoter methylation, in adrenocortical carcinoma cells.

Authors:  Insoo Suh; Julie Weng; Gustavo Fernandez-Ranvier; Wen T Shen; Quan-Yang Duh; Orlo H Clark; Electron Kebebew
Journal:  Arch Surg       Date:  2010-03

Review 2.  Review paper: origin and molecular pathology of adrenocortical neoplasms.

Authors:  M Bielinska; H Parviainen; S Kiiveri; M Heikinheimo; D B Wilson
Journal:  Vet Pathol       Date:  2009-03       Impact factor: 2.221

3.  VRK2 inhibits mitogen-activated protein kinase signaling and inversely correlates with ErbB2 in human breast cancer.

Authors:  Isabel F Fernández; Sandra Blanco; José Lozano; Pedro A Lazo
Journal:  Mol Cell Biol       Date:  2010-08-02       Impact factor: 4.272

Review 4.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

Review 5.  Regulation of the adrenocortical stem cell niche: implications for disease.

Authors:  Elisabeth M Walczak; Gary D Hammer
Journal:  Nat Rev Endocrinol       Date:  2014-10-07       Impact factor: 43.330

Review 6.  Adrenal cortical carcinoma.

Authors:  A P Dackiw; J E Lee; R F Gagel; D B Evans
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

Review 7.  Genetic background of adrenocortical tumor development.

Authors:  M Kjellman; C Larsson; M Bäckdahl
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

Review 8.  Adrenocortical carcinoma: a clinician's update.

Authors:  Martin Fassnacht; Rossella Libé; Matthias Kroiss; Bruno Allolio
Journal:  Nat Rev Endocrinol       Date:  2011-03-08       Impact factor: 43.330

9.  Isolated familial somatotropinoma: 11q13-loh and gene/protein expression analysis suggests a possible involvement of aip also in non-pituitary tumorigenesis.

Authors:  Rodrigo A Toledo; Berenice B Mendonca; Maria Candida B V Fragoso; Iberê C Soares; Madson Q Almeida; Michelle B Moraes; Delmar M Lourenço; Venâncio A F Alves; Marcello D Bronstein; Sergio P A Toledo
Journal:  Clinics (Sao Paulo)       Date:  2010-04       Impact factor: 2.365

Review 10.  Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene.

Authors:  Albert Beckers; Lauri A Aaltonen; Adrian F Daly; Auli Karhu
Journal:  Endocr Rev       Date:  2013-01-31       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.